RU2209064C2 - Новое применение в медицинских целях - Google Patents
Новое применение в медицинских целях Download PDFInfo
- Publication number
- RU2209064C2 RU2209064C2 RU98101105/14A RU98101105A RU2209064C2 RU 2209064 C2 RU2209064 C2 RU 2209064C2 RU 98101105/14 A RU98101105/14 A RU 98101105/14A RU 98101105 A RU98101105 A RU 98101105A RU 2209064 C2 RU2209064 C2 RU 2209064C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- active ingredient
- pharmaceutical preparation
- symptoms
- Prior art date
Links
- 201000006549 dyspepsia Diseases 0.000 claims abstract 5
- 208000024891 symptom Diseases 0.000 claims abstract 5
- 239000002253 acid Substances 0.000 claims abstract 4
- 210000004877 mucosa Anatomy 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 230000001771 impaired effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036454 renin-angiotensin system Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- NVEMWFQWQAXZDZ-UHFFFAOYSA-N CCc1nc(c(C)cc(C)c2)c2[n]1C Chemical compound CCc1nc(c(C)cc(C)c2)c2[n]1C NVEMWFQWQAXZDZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Изобретение относится к медицине, а именно к гастроэнтерологии, и касается лечения симптомов функциональной диспепсии, связанных с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту. Для этого используют производные бифенилтетразола общей формулы I, являющиеся антагонистами рецепторов ангиотензина II 1-го типа. Изобретение позволяет уменьшить симптомы функциональной диспепсии путем воздействия на ренин-ангиотензиновую систему. 3 с. и 7 з.п.ф-лы, 1 табл.
Description
Текст описания в факсимильном виде (см. графическую часть). Т3
Claims (10)
1. Применение соединения общей формулы I
в которой А представляет собой
или его физиологически приемлемой соли и/или стереохимического изомера в качестве активного ингредиента для производства медикамента, уменьшающего симптомы функциональной диспепсии, связанные с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту.
в которой А представляет собой
или его физиологически приемлемой соли и/или стереохимического изомера в качестве активного ингредиента для производства медикамента, уменьшающего симптомы функциональной диспепсии, связанные с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту.
2. Применение по п. 1 соединения формулы I, в которой А представляет собой I:1.
3. Применение по п. 1 соединения формулы I, в которой А представляет собой I:5.
4. Фармацевтический препарат для применения при профилактике и/или лечении симптомов функциональной диспепсии, связанных с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту, в котором активным ингредиентом является соединение по п.1.
5. Фармацевтический препарат по п.4 в форме стандартной дозы.
6. Фармацевтический препарат по пп.4 и 5, содержащий активный ингредиент в сочетании с фармацевтически приемлемым носителем.
7. Фармацевтический препарат по пп.4-6, содержащий в качестве активного ингредиента соединение формулы I, в которой А представляет собой I:1.
8. Фармацевтический препарат по пп.4-6, содержащий в качестве активного ингредиента соединение формулы I, в которой А представляет собой I:5.
9. Способ профилактики и лечения симптомов функциональной диспепсии, связанных с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту, у млекопитающих, включая человека, при котором эффективным количеством соединения по п.1 воздействуют на хозяина, нуждающегося в такой профилактике и лечении.
10. Способ по п.9, отличающийся тем, что воздействуют соединением формулы I, в которой А представляет собой I:1 или I:5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502219A SE9502219D0 (sv) | 1995-06-19 | 1995-06-19 | Novel medical use |
| SE9502219.0 | 1995-06-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU98101105A RU98101105A (ru) | 1999-12-10 |
| RU2209064C2 true RU2209064C2 (ru) | 2003-07-27 |
Family
ID=20398663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98101105/14A RU2209064C2 (ru) | 1995-06-19 | 1996-06-10 | Новое применение в медицинских целях |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6096772A (ru) |
| EP (1) | EP0840607B1 (ru) |
| JP (1) | JPH11507921A (ru) |
| KR (1) | KR19990023021A (ru) |
| CN (1) | CN1091595C (ru) |
| AT (1) | ATE214925T1 (ru) |
| AU (1) | AU706660B2 (ru) |
| BR (1) | BR9608472A (ru) |
| CA (1) | CA2225175A1 (ru) |
| CZ (1) | CZ289400B6 (ru) |
| DE (1) | DE69620186T2 (ru) |
| DK (1) | DK0840607T3 (ru) |
| EE (1) | EE03385B1 (ru) |
| ES (1) | ES2173294T3 (ru) |
| HU (1) | HUP9901448A3 (ru) |
| IL (1) | IL122659A (ru) |
| IS (1) | IS4619A (ru) |
| MY (1) | MY114716A (ru) |
| NO (1) | NO975922L (ru) |
| NZ (1) | NZ310606A (ru) |
| PT (1) | PT840607E (ru) |
| RU (1) | RU2209064C2 (ru) |
| SE (1) | SE9502219D0 (ru) |
| SK (1) | SK172197A3 (ru) |
| UA (1) | UA55387C2 (ru) |
| WO (1) | WO1997000070A1 (ru) |
| ZA (1) | ZA964690B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277112B1 (en) | 1996-07-16 | 2001-08-21 | Arthrocare Corporation | Methods for electrosurgical spine surgery |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| US6602248B1 (en) | 1995-06-07 | 2003-08-05 | Arthro Care Corp. | Methods for repairing damaged intervertebral discs |
| US7393351B2 (en) | 1995-06-07 | 2008-07-01 | Arthrocare Corporation | Apparatus and methods for treating cervical inter-vertebral discs |
| US20050004634A1 (en) | 1995-06-07 | 2005-01-06 | Arthrocare Corporation | Methods for electrosurgical treatment of spinal tissue |
| US7357798B2 (en) | 1996-07-16 | 2008-04-15 | Arthrocare Corporation | Systems and methods for electrosurgical prevention of disc herniations |
| US6726684B1 (en) | 1996-07-16 | 2004-04-27 | Arthrocare Corporation | Methods for electrosurgical spine surgery |
| SE9800550D0 (sv) * | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| US20030158545A1 (en) | 2000-09-28 | 2003-08-21 | Arthrocare Corporation | Methods and apparatus for treating back pain |
| BR0102252B1 (pt) * | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
| AU2002362310A1 (en) | 2001-09-14 | 2003-04-01 | Arthrocare Corporation | Methods and apparatus for treating intervertebral discs |
| US7413751B2 (en) * | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| DE602004029982D1 (de) * | 2003-01-30 | 2010-12-23 | Lek Pharmaceuticals | Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren |
| EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| US8979838B2 (en) | 2010-05-24 | 2015-03-17 | Arthrocare Corporation | Symmetric switching electrode method and related system |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| GB2263635A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
| GB2263637A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists |
| GB2263638A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists |
| US5250558A (en) * | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
| GB2263639A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| DE4203872A1 (de) * | 1992-02-11 | 1993-08-12 | Thomae Gmbh Dr K | Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5212195A (en) * | 1992-05-13 | 1993-05-18 | Syntex (U.S.A.) Inc. | Substituted indole antagonists derivatives which are angiotensin II |
| US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
-
1995
- 1995-06-19 SE SE9502219A patent/SE9502219D0/xx unknown
-
1996
- 1996-06-05 ZA ZA964690A patent/ZA964690B/xx unknown
- 1996-06-10 EP EP96918965A patent/EP0840607B1/en not_active Expired - Lifetime
- 1996-06-10 AU AU11840/97A patent/AU706660B2/en not_active Ceased
- 1996-06-10 HU HU9901448A patent/HUP9901448A3/hu unknown
- 1996-06-10 WO PCT/SE1996/000758 patent/WO1997000070A1/en not_active Ceased
- 1996-06-10 KR KR1019970709491A patent/KR19990023021A/ko not_active Ceased
- 1996-06-10 ES ES96918965T patent/ES2173294T3/es not_active Expired - Lifetime
- 1996-06-10 DK DK96918965T patent/DK0840607T3/da active
- 1996-06-10 CN CN96196137A patent/CN1091595C/zh not_active Expired - Fee Related
- 1996-06-10 DE DE69620186T patent/DE69620186T2/de not_active Expired - Fee Related
- 1996-06-10 RU RU98101105/14A patent/RU2209064C2/ru not_active IP Right Cessation
- 1996-06-10 CZ CZ19973730A patent/CZ289400B6/cs not_active IP Right Cessation
- 1996-06-10 EE EE9700366A patent/EE03385B1/xx not_active IP Right Cessation
- 1996-06-10 AT AT96918965T patent/ATE214925T1/de not_active IP Right Cessation
- 1996-06-10 IL IL12265996A patent/IL122659A/xx not_active IP Right Cessation
- 1996-06-10 NZ NZ310606A patent/NZ310606A/en unknown
- 1996-06-10 CA CA002225175A patent/CA2225175A1/en not_active Abandoned
- 1996-06-10 BR BR9608472A patent/BR9608472A/pt not_active Application Discontinuation
- 1996-06-10 US US08/702,522 patent/US6096772A/en not_active Expired - Fee Related
- 1996-06-10 PT PT96918965T patent/PT840607E/pt unknown
- 1996-06-10 JP JP9502982A patent/JPH11507921A/ja active Pending
- 1996-06-10 SK SK1721-97A patent/SK172197A3/sk unknown
- 1996-06-19 MY MYPI96002480A patent/MY114716A/en unknown
- 1996-10-06 UA UA97126085A patent/UA55387C2/ru unknown
-
1997
- 1997-11-25 IS IS4619A patent/IS4619A/is unknown
- 1997-12-16 NO NO975922A patent/NO975922L/no not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| ЕР 0253310 А2 (DU PONT), 20.01.1998. ЕР 04591036 A1 (TAKEDA CHEMICAL INDUSTRIES LTD), 04.12.1991. ГЕЛЛЕР Л.И. и др. Синдром неязвенной диспепсии, Клиническая медицина, 1993, т.71, №1, с.22-25. КОРЖАК О.Л. и др. Фармакологический анализ эффекта ангиотензина на стимуляцию желудочной секреции, Физиологический журнал Украины, 1994, т.40, №5-6, реферат. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2209064C2 (ru) | Новое применение в медицинских целях | |
| ATE260646T1 (de) | Schnell zerfallende orale dosierungsform | |
| RU2220723C2 (ru) | Средство и способ лечения или профилактики артериосклероза | |
| RU97115893A (ru) | Препарат местного применения | |
| EE04800B1 (et) | Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks | |
| RU2000100361A (ru) | Натриевая соль омепразола | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| RU94041223A (ru) | Средство для лечения мотонейроновых заболеваний | |
| CA2326517A1 (en) | New galenic preparations of meloxicam for oral administration | |
| EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
| RU2001111880A (ru) | Композиции для перорального введения, содержащие луфенурон и нитенпирам, для борьбы с блохами | |
| ES2171469T3 (es) | Composicion administrada por via nasal y preparacion que la contiene. | |
| RU98101105A (ru) | Новое применение в медицинских целях | |
| EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
| RU2002117649A (ru) | Фармацевтические композиции, содержащие золмитриптан | |
| RU2000116547A (ru) | Применение замещенных аминометил-хроманов для предотвращения дегенерации и для ускорения регенерации нервных клеток | |
| KR20040000446A (ko) | 중간 용량의 ｌｈｒｈ 길항제를 사용한 치매 및 퇴행성신경질환의 치료 | |
| RU94045866A (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения | |
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| RU97120700A (ru) | Новое фармакологическое применение антагонистов a-ii рецептора | |
| RU98103388A (ru) | (r)-5-бром-n-(1-этил-4-метилгексагидро-1н-1,4-диазепин-6-ил)-2-метокси-6-м етиламино-3-пиридинкарбоксамид, способ его получения и фармацевтическая композиция, содержащая указанное соединение | |
| ZA922910B (en) | Heterocylic pharmaceutical compounds preparation and use | |
| RU2005105302A (ru) | Композиция бицифадина | |
| RU2011131532A (ru) | Способ лечения бессонницы | |
| KR900701278A (ko) | 바이러스 감염 치료용 담즙산 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20030611 |